Literature DB >> 21321266

PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?

Ambros J Beer1, Markus Schwaiger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321266     DOI： 10.2967/jnumed.110.078568

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  7 in total

1.  Pilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?

Authors:  Peter L Choyke
Journal:  Radiology       Date:  2011-07       Impact factor: 11.105

2.  Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Authors:  Yang Zhou; Young-Seung Kim; Xin Lu; Shuang Liu
Journal:  Bioconjug Chem       Date:  2012-03-06       Impact factor: 4.774

3.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

Review 4.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 5.  Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2015-08-03       Impact factor: 4.774

6.  Imaging integrin αvβ 3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe.

Authors:  Hua Wu; Haojun Chen; Dongfeng Pan; Yufei Ma; Sheng Liang; Ying Wan; Ya Fang
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

7.  Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.

Authors:  Shundong Ji; Yumin Zheng; Guoqiang Shao; Yang Zhou; Shuang Liu
Journal:  Theranostics       Date:  2013-10-12       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.